PriceTargets.com logo

Arcellx - ACLX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $105.93
  • Forecasted Upside: 40.23%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 13 Buy Ratings
  • 2 Strong Buy Ratings
$75.54 As of 12/20/2024 06:31 PM ET
▲ +0.33 (0.44%)

This chart shows the closing price for ACLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcellx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACLX

Analyst Price Target is $105.93
▲ +40.23% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Arcellx in the last 3 months. The average price target is $105.93, with a high forecast of $136.00 and a low forecast of $73.00. The average price target represents a 40.23% upside from the last price of $75.54.

This chart shows the closing price for ACLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 15 contributing investment analysts is to buy stock in Arcellx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 1 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 2 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 2 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024UBS GroupBoost TargetBuy ➝ Buy$106.00 ➝ $114.00
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
12/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00 ➝ $105.00
11/29/2024BarclaysUpgradeStrong-Buy
11/12/2024Truist FinancialBoost TargetBuy ➝ Buy$87.00 ➝ $136.00
11/8/2024Piper SandlerBoost TargetOverweight ➝ Overweight$91.00 ➝ $115.00
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$96.00 ➝ $96.00
11/6/2024HC WainwrightBoost TargetBuy ➝ Buy$80.00 ➝ $95.00
11/6/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$77.00 ➝ $106.00
11/6/2024Bank of AmericaBoost TargetBuy ➝ Buy$84.00 ➝ $100.00
11/6/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$81.00 ➝ $106.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$96.00 ➝ $96.00
10/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00 ➝ $96.00
10/18/2024Stifel NicolausBoost TargetBuy ➝ Buy$83.00 ➝ $122.00
10/17/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$85.00 ➝ $115.00
10/8/2024Redburn AtlanticInitiated CoverageBuy$109.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/3/2024Cantor FitzgeraldInitiated CoverageOverweight
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00 ➝ $81.00
7/22/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
6/18/2024Truist FinancialReiterated RatingBuy ➝ Buy$87.00 ➝ $87.00
5/31/2024Piper SandlerInitiated CoverageOverweight$70.00
5/15/2024Stifel NicolausBoost TargetBuy ➝ Buy$82.00 ➝ $83.00
5/14/2024Evercore ISIInitiated CoverageOutperform$85.00
5/13/2024Evercore ISIUpgradeStrong-Buy
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$82.00 ➝ $80.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00
4/4/2024ScotiabankReiterated RatingOutperform$82.00
3/18/2024Needham & Company LLCBoost TargetBuy ➝ Buy$72.00 ➝ $81.00
3/14/2024Stifel NicolausReiterated RatingBuy ➝ Buy$82.00
3/7/2024Morgan StanleyInitiated CoverageOverweight$81.00
3/5/2024Truist FinancialBoost TargetBuy ➝ Buy$57.00 ➝ $87.00
2/29/2024HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $82.00
2/29/2024ScotiabankBoost TargetOutperform$82.00
2/29/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$66.00 ➝ $85.00
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$62.00 ➝ $73.00
2/29/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$63.00 ➝ $77.00
2/29/2024Needham & Company LLCBoost TargetBuy ➝ Buy$71.00 ➝ $72.00
1/4/2024Needham & Company LLCBoost TargetBuy ➝ Buy$65.00 ➝ $71.00
12/19/2023ScotiabankInitiated CoverageSector Outperform$66.00
12/11/2023Needham & Company LLCBoost TargetBuy ➝ Buy$60.00 ➝ $65.00
11/15/2023Needham & Company LLCBoost TargetBuy ➝ Buy$51.00 ➝ $60.00
11/15/2023HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $60.00
10/30/2023TD CowenInitiated CoverageOutperform
10/17/2023UBS GroupInitiated CoverageBuy$52.00
10/12/2023Leerink PartnrsReiterated RatingOutperform
8/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$51.00
8/15/2023Stifel NicolausLower TargetBuy ➝ Buy$54.00 ➝ $52.00
8/15/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$40.00 ➝ $52.00
8/15/2023HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $50.00
6/20/2023Truist FinancialLower Target$60.00 ➝ $57.00
6/20/2023Robert W. BairdLower Target$55.00 ➝ $40.00
5/18/2023Truist FinancialInitiated CoverageBuy$60.00
5/10/2023Bank of AmericaBoost Target$39.00 ➝ $50.00
5/9/2023Needham & Company LLCBoost Target$35.00 ➝ $51.00
5/9/2023HC WainwrightBoost Target$40.00 ➝ $49.00
5/9/2023BarclaysBoost TargetOverweight$38.00 ➝ $49.00
4/24/2023GuggenheimBoost Target$45.00 ➝ $58.00
4/19/2023Canaccord Genuity GroupBoost TargetBuy$34.00 ➝ $40.00
4/13/2023Robert W. BairdInitiated CoverageOutperform$39.00
3/30/2023HC WainwrightLower TargetBuy$42.00 ➝ $40.00
3/30/2023Leerink PartnersBoost TargetOutperform$35.00 ➝ $39.00
3/30/2023Needham & Company LLCReiterated RatingBuy$35.00
3/30/2023SVB SecuritiesBoost Target$35.00 ➝ $39.00
3/13/2023Stifel NicolausInitiated CoverageBuy$43.00
2/13/2023HC WainwrightInitiated CoverageBuy$42.00
12/13/2022Bank of AmericaReiterated RatingBuy$29.00 ➝ $37.00
12/12/2022Canaccord Genuity GroupBoost Target$32.00 ➝ $34.00
12/12/2022Needham & Company LLCBoost TargetBuy$31.00 ➝ $35.00
12/12/2022BarclaysBoost TargetOverweight$25.00 ➝ $38.00
12/9/2022Piper SandlerBoost Target$96.00 ➝ $104.00
11/24/2022Leerink PartnersLower Target$35.00
10/31/2022GuggenheimInitiated CoverageBuy$36.00
10/27/2022Needham & Company LLCInitiated CoverageBuy$31.00
7/20/2022Canaccord Genuity GroupInitiated CoverageBuy$32.00
6/23/2022Leerink PartnersLower TargetOutperform$47.00 ➝ $38.00
3/29/2022Leerink PartnersLower TargetOutperform$47.00 ➝ $44.00
3/2/2022BarclaysInitiated CoverageOverweight
3/1/2022William BlairReiterated RatingOutperform
3/1/2022Leerink PartnersInitiated CoverageOutperform$47.00
3/1/2022Bank of AmericaInitiated CoverageBuy$24.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.18 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 12 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 13 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 15 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 13 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 18 very positive mentions
  • 29 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 26 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 26 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Arcellx logo
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $75.54
Low: $73.40
High: $76.41

50 Day Range

MA: $88.59
Low: $75.21
High: $106.53

52 Week Range

Now: $75.54
Low: $47.88
High: $107.37

Volume

1,372,259 shs

Average Volume

491,145 shs

Market Capitalization

$4.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcellx?

The following equities research analysts have issued stock ratings on Arcellx in the last year: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Evercore ISI, HC Wainwright, Morgan Stanley, Needham & Company LLC, Piper Sandler, Redburn Atlantic, Robert W. Baird, Scotiabank, Stifel Nicolaus, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for ACLX.

What is the current price target for Arcellx?

0 Wall Street analysts have set twelve-month price targets for Arcellx in the last year. Their average twelve-month price target is $105.93, suggesting a possible upside of 40.2%. Truist Financial Co. has the highest price target set, predicting ACLX will reach $136.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $73.00 for Arcellx in the next year.
View the latest price targets for ACLX.

What is the current consensus analyst rating for Arcellx?

Arcellx currently has 13 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACLX will outperform the market and that investors should add to their positions of Arcellx.
View the latest ratings for ACLX.

What other companies compete with Arcellx?

Other companies that are similar to Arcellx include BeiGene, Moderna, Viatris, Summit Therapeutics and Genmab A/S. Learn More about companies similar to Arcellx.

How do I contact Arcellx's investor relations team?

The company's listed phone number is 240-327-0603 and its investor relations email address is [email protected]. The official website for Arcellx is arcellx.com. Learn More about contacing Arcellx investor relations.